<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04012905</url>
  </required_header>
  <id_info>
    <org_study_id>17-249</org_study_id>
    <secondary_id>2018-000344-25</secondary_id>
    <nct_id>NCT04012905</nct_id>
  </id_info>
  <brief_title>Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering</brief_title>
  <acronym>CORTODOSE</acronym>
  <official_title>A Randomized, Controled, Open Label Trial: Comparison Between Two Standardized Corticosteroids Tapering, Respectively Short (North American) and Long (European), in Giant Cell Arteritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amiens University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Hospital Saint Quentin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Hospital, Valenciennes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Hospital, Lisieux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Corticosteroid therapy has always been the standard treatment for giant cell arteritis (GCA),&#xD;
      with very good initial clinical efficacy but a high relapse rate when it declines.&#xD;
&#xD;
      The target population of this condition, often elderly, is particularly exposed to the&#xD;
      numerous undesirable effects of corticosteroid therapy, and this especially as its duration&#xD;
      lengthens with the re-increases of doses according to relapses: metabolic complications,&#xD;
      osteo-muscular , infectious or neuropsychiatric.&#xD;
&#xD;
      Investigators propose to compare prospectively the results of a &quot;conventional&quot; corticosteroid&#xD;
      regimen as recommended by European societies, to those of a &quot;lighter and / or shorter&quot;&#xD;
      scheme, inspired by recent North American trials. , including the largest prospective global&#xD;
      study in the field. Investigators hypothesize non-inferiority of the lightened regimen for&#xD;
      relapse rate without relapse at S52, but with a decrease in treatment-related adverse events&#xD;
      whose cumulative doses should be lower.&#xD;
&#xD;
      Investigators therefore plan to include prospectively over 3 years 150 patients, 75 for each&#xD;
      of the two arms, with a newly diagnosed ACG. A randomization of the treatment arm will be&#xD;
      performed and a predefined pattern of cortisone adapted to body weight will be given to the&#xD;
      patient. Relapse rates, maintenance of remission, cumulative doses of cortisone and adverse&#xD;
      effects of treatment will be analyzed at the 52nd week of the introduction of corticosteroid&#xD;
      therapy. An interim analysis is planned at S28.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of giant cell arteritis (GCA) relies on the use of glucocorticoids (GC), with a&#xD;
      very good clinical response at treatment initiation. However, relapses at GC tapering are&#xD;
      frequent. GCA population is elderly, frequently over 80 years, and is especially affected by&#xD;
      GC-related side effects, that increase proportionally with treatment duration. Thus,&#xD;
      metabolic, musculo-skeletal, infectious or neuro-psychiatric complications are frequent&#xD;
      during prolonged GC use.&#xD;
&#xD;
      After GC introduction, gradual tapering is scheduled, provided the disease remains clinically&#xD;
      and biologically controlled. In France, guidelines recommend tapering GC on an 18-24 months&#xD;
      timeframe, while other countries, such as the USA, usually taper GC over a shorter period,&#xD;
      often 6-8 months. Few comparative data exist on the relapse rates or the GC-related side&#xD;
      effects in both settings. In this prospective multicenter study, two GC-tapering schedules&#xD;
      are planned: patients in one arm (short treatment) will be treated for 28 weeks, while&#xD;
      patients in the second arm will be treated for 52 weeks. Each starting dose of GC and&#xD;
      tapering doses will be adapted to body weight. The primary endpoint is to compare the&#xD;
      remission rate without relapse at W52 between the two groups and the secondary endpoints are:&#xD;
      1) cumulative GC doses at W52; 2) GC-related side effects and 3) number of relapses (minor&#xD;
      and severe) in both arms at W52.&#xD;
&#xD;
      The results of this study might considerably modify future French clinical practice if&#xD;
      investigators confirm that a shorter GC treatment does not significantly impact the disease&#xD;
      course while reducing GC-related side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 5, 2020</start_date>
  <completion_date type="Anticipated">January 2027</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient in complete remission over a follow up of 52 weeks, without relapse</measure>
    <time_frame>Baseline up to 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>First relapses rate at S28 and S52</measure>
    <time_frame>Weeks 28 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second relapses rate at S28 and S52</measure>
    <time_frame>Weeks 28 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delay between first and second relapses</measure>
    <time_frame>Baseline up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative and the average dose of prednisone used</measure>
    <time_frame>Weeks 28 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patient with corticosteroids dependence at week 52</measure>
    <time_frame>Baseline up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety according CTCAE v5.0</measure>
    <time_frame>Baseline up to 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Giant Cell Arteritis</condition>
  <arm_group>
    <arm_group_label>Short tapering corticosteroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Corticosteroid taper over 28 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long tapering corticosteroids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Corticosteroid taper over 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroids for Systemic Use</intervention_name>
    <description>Corticosteroids tapering over 28 weeks:&#xD;
J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,5 mg/kg S6 = 0,4 mg/kg S8 = 0,3 mg/kg S10 = 0,25 mg/kg S12 = 0,2 mg/kg S14 = 0,15 mg/kg S16 = 0,15 mg/kg S20 = 0,1 mg/kg S24 = 0,05 mg/kg S28 = 0 mg/kg&#xD;
Corticosteroids tapering over 52 weeks:&#xD;
J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,6 mg/kg S6 = 0,5 mg/kg S8 = 0,4 mg/kg S10 = 0,3 mg/kg S12 = 0,25 mg/kg S14 = 0,2 mg/kg S16 = 0,175 mg/kg S20 = 0,15 mg/kg S24 = 0,125 mg/kg S28 = 0,01 mg/kg S32 to S52: - 1mg per month</description>
    <arm_group_label>Long tapering corticosteroids</arm_group_label>
    <arm_group_label>Short tapering corticosteroids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 50 years&#xD;
&#xD;
          -  Patient with temporal arteritis giant cell match 2 of the 4 criteria of the American&#xD;
             College of Rheumatology (ACR) that given :&#xD;
&#xD;
               -  a temporal artery biopsy compatible with a diagnosis of CAG or&#xD;
&#xD;
               -  an abdominal thoracic aortitis diagnosed by Angio CT, MR angiography or PET&#xD;
                  scanner or&#xD;
&#xD;
               -  Echo Doppler compatible with a diagnosis of CAG&#xD;
&#xD;
          -  Oral corticosteroid treatment started up to 14 days, the initial dose is less or equal&#xD;
             to 1 mg / Kg&#xD;
&#xD;
          -  Patient wo has given its written consent Patient affiliated with a social security&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects checking one of the criteria for non-inclusion may be eligible to participate in&#xD;
        the research. These criteria may include:&#xD;
&#xD;
          -  Early treatment of CAG disease with a dose&gt; 1 mg / kg whatever the duration&#xD;
&#xD;
          -  Corticosteroids already started over 14 days&#xD;
&#xD;
          -  Giant arteritis cell on relapse&#xD;
&#xD;
          -  dementia syndrome&#xD;
&#xD;
          -  No compliant patient&#xD;
&#xD;
          -  Patients who live more than 150 km from the investigation center&#xD;
&#xD;
          -  Person under judicial protection, guardianship&#xD;
&#xD;
          -  Hypersensitivity to prednisone or any of its excipients&#xD;
&#xD;
          -  Infection requiring an systemic treatment&#xD;
&#xD;
          -  Evolutive viroses (Hepatitis, Herpes, varicella-zoster virus)&#xD;
&#xD;
          -  Immunization with live vaccines / mitigated during the 8 weeks preceding inclusion&#xD;
&#xD;
          -  Pregnancy, breastfeeding women or women of childbearing potential not using&#xD;
             contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hubert De BOYSSON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Caen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hubert De BOYSSON, MD</last_name>
    <phone>02 31 06 57 32</phone>
    <phone_ext>+33</phone_ext>
    <email>deboysson-h@chu-caen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Audrey SULTAN, PhD</last_name>
    <phone>02 31 06 33 58</phone>
    <phone_ext>+33</phone_ext>
    <email>sultan-a@chu-caen.fr</email>
  </overall_contact_backup>
  <reference>
    <citation>Bienvenu B, Ly KH, Lambert M, Agard C, AndrÃ© M, Benhamou Y, Bonnotte B, de Boysson H, Espitia O, Fau G, Fauchais AL, Galateau-SallÃ© F, Haroche J, HÃ©ron E, LapÃ©bie FX, Liozon E, Luong Nguyen LB, Magnant J, Manrique A, Matt M, de Menthon M, Mouthon L, PuÃ©chal X, Pugnet G, Quemeneur T, RÃ©gent A, Saadoun D, Samson M, SÃ¨ne D, Smets P, Yelnik C, Sailler L, Mahr A; Groupe d'Ã‰tude FranÃ§ais des ArtÃ©rites des gros Vaisseaux, under the Aegis of the FiliÃ¨re des Maladies Auto-Immunes et Auto-Inflammatoires Rares. Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev Med Interne. 2016 Mar;37(3):154-65. doi: 10.1016/j.revmed.2015.12.015. Epub 2016 Jan 29.</citation>
    <PMID>26833145</PMID>
  </reference>
  <reference>
    <citation>de Boysson H, Aouba A. Abatacept as Adjunctive Therapy for the Treatment of Giant Cell Arteritis: Comment on the Article by Langford et al. Arthritis Rheumatol. 2017 Jul;69(7):1504. doi: 10.1002/art.40105. Epub 2017 May 10.</citation>
    <PMID>28324917</PMID>
  </reference>
  <reference>
    <citation>van der Goes MC, Jacobs JW, Boers M, Andrews T, Blom-Bakkers MA, Buttgereit F, Caeyers N, Cutolo M, Da Silva JA, Guillevin L, Kirwan JR, Rovensky J, Severijns G, Webber S, Westhovens R, Bijlsma JW. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010 Nov;69(11):1913-9. doi: 10.1136/ard.2009.124958. Epub 2010 Aug 6.</citation>
    <PMID>20693273</PMID>
  </reference>
  <reference>
    <citation>Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003 Oct 15;49(5):703-8.</citation>
    <PMID>14558057</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 5, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Giant Cell Arteritis</keyword>
  <keyword>Horton disease</keyword>
  <keyword>Corticosteroids treatment</keyword>
  <keyword>Prednisone</keyword>
  <keyword>Relapse</keyword>
  <keyword>Side effect</keyword>
  <keyword>Cumulative doses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Arteritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All individual data will be analyzed in University Hospital, Caen</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

